WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007016306) HMGCoA REDUCTASE INHIBITOR CODRUGS AND USES THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/016306    International Application No.:    PCT/US2006/029331
Publication Date: 08.02.2007 International Filing Date: 28.07.2006
IPC:
A61K 47/48 (2006.01)
Applicants: PSIVIDA INC. [US/US]; 400 Pleasant Street, Watertown, MA 02472 (US) (For All Designated States Except US).
CYNKOWSKI, Tadeusz [US/US]; (US) (For US Only).
CYNKOWSKA, Grazyna [US/US]; (US) (For US Only).
SMITH, Thomas, J. [CA/US]; (US) (For US Only)
Inventors: CYNKOWSKI, Tadeusz; (US).
CYNKOWSKA, Grazyna; (US).
SMITH, Thomas, J.; (US)
Agent: VINCENT, Matthew, P.; FISH & NEAVE IP GROUP, ROPES & GRAY LLP, One International Place, Boston, MA 02110-2624 (US)
Priority Data:
60/704,263 01.08.2005 US
Title (EN) HMGCoA REDUCTASE INHIBITOR CODRUGS AND USES THEREOF
(FR) COMPOSES INHIBITEURS DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE- INHIBITEURS DE LA HMGCOA REDUCTASE
Abstract: front page image
(EN)A compound that contains at least two independently active pharmacological moieties, either covalently conjoined through a physiologically labile linker or ionically associated. One pharmacological moiety is an HMGCoA reductase inhibitor (such as a statin). Another pharmacological moiety is an angiotensin converting enzyme inhibitor.
(FR)L'invention concerne un composé contenant au moins deux fractions pharmacologiques indépendamment actives, soit liées de manière covalente via un liant physiologiquement labile soit ioniquement associées. Une fraction pharmacologiquement active est un inhibiteur de la HMGCoA réductase (tel qu'une statine). L'autre fraction pharmacologiquement est un inhibiteur de l'enzyme de conversion de l'angiotensine.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)